Chronic bronchitis is a long-term inflammatory condition of the airways, primarily characterized by a persistent cough that produces mucus for at least three months each year over two consecutive years. It is often caused by prolonged exposure to irritants, especially cigarette smoke, leading to airway inflammation and mucus overproduction. This condition is a type of chronic obstructive pulmonary disease (COPD) and can result in difficulty breathing and increased susceptibility to lung infections. The management of the condition typically focuses on alleviating symptoms and preventing exacerbations. Moreover, the rising prevalence of the condition is anticipated to positively impact the pipeline landscape for chronic bronchitis drugs.
Major companies involved in the chronic bronchitis treatment market include Incyte Biosciences Japan GK, Gala Therapeutics, Inc., and Pharmacyclics LLC.
Leading drugs currently under the pipeline include ibrutinib and axatilimab, among others.
The increasing cases of chronic bronchitis and the rising technological advancements are poised to positively influence the chronic bronchitis pipeline landscape.
The Chronic Bronchitis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into chronic bronchitis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for chronic bronchitis. The chronic bronchitis report assessment includes the analysis of over 25 pipeline drugs and 10+ companies. The chronic bronchitis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with chronic bronchitis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to chronic bronchitis.
Chronic bronchitis is characterized by persistent inflammation of the airways due to long-term exposure to irritants, leading to several pathological changes. This includes hypertrophy of mucus-secreting glands and increased goblet cell numbers, resulting in excessive mucus production. The airway walls become inflamed, narrowing the bronchioles and causing airflow obstruction. Ciliary function is impaired, making mucus clearance difficult and increasing infection risk. Over time, chronic inflammation can lead to irreversible airway damage and pulmonary hypertension, contributing to respiratory failure and heart complications like cor pulmonale.
The treatment plan for chronic bronchitis aims to relieve symptoms, improve lung function, and prevent disease progression. Smoking cessation is the most critical step to halt further lung damage. Medications such as bronchodilators and corticosteroids are prescribed to reduce airway inflammation and improve airflow, while antibiotics may be used for bacterial infections. Pulmonary rehabilitation programs, including exercise training and education, help enhance respiratory health. Lifestyle modifications like maintaining a healthy diet, staying physically active, and avoiding irritants are essential for effective management of the condition. Further, the rising focus on the development of chronic bronchitis emerging drugs and the advances in the understanding of the molecular pathogenesis of the disease are expected to support the pipeline expansion in the coming years.
Chronic bronchitis affects approximately 3.6% of adults aged 18 and older, translating to about 9 million individuals in the United States as of 2018. The prevalence is notably higher among non-Hispanic white individuals, women, and those aged 65 and older. Globally, estimates indicate that chronic bronchitis symptoms can vary significantly, with prevalence rates ranging from less than 1% in some regions to over 10% in others. Factors such as smoking, air pollution, and occupational exposures contribute to its incidence, highlighting the importance of targeted public health interventions.
This section of the report covers the analysis of chronic bronchitis drug candidates based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials, with a substantial number of chronic bronchitis drugs undergoing clinical development. Out of the total drugs in the chronic bronchitis pipeline, about 44% are in Phase 2, making it the most active stage of development. Phase 3 follows with around 24%, while Phase 1 accounts for roughly 16% of the drugs. Phase 4 makes up about 15%, and only about 1% are in the Early Phase 1 stage. This shows that most research is currently focused on mid-stage clinical trials.
The drug molecule categories covered under chronic bronchitis pipeline analysis include small molecules, cell therapy, peptides, polymers, and gene therapies, among others. The chronic bronchitis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials.
The EMR report for the chronic bronchitis drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed chronic bronchitis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in chronic bronchitis clinical trials:
Major drugs currently in the drug pipeline are as follows:
Ibrutinib, manufactured by Pharmacyclics LLC, is an oral Bruton’s tyrosine kinase (BTK) inhibitor. It is being evaluated for its anti-inflammatory properties in treating chronic bronchitis by reducing immune cell activation and airway inflammation. Originally approved for B-cell malignancies, Ibrutinib is now under clinical trials for chronic respiratory conditions. The drug aims to modulate immune responses, potentially decreasing exacerbations and improving lung function in chronic bronchitis patients.
Axatilimab, developed by Incyte Biosciences Japan GK, is a monoclonal antibody targeting colony-stimulating factor-1 receptor (CSF-1R). It is being evaluated for its potential to reduce inflammation and fibrosis in chronic bronchitis by inhibiting macrophage activity. The drug aims to alleviate airway inflammation and tissue damage, potentially improving lung function and reducing disease progression. Axatilimab is currently in clinical trials to assess its safety, efficacy, and tolerability in patients with chronic bronchitis.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Chronic Bronchitis Drug Pipeline Report provides a strategic overview of the latest and future landscape of treatments for chronic bronchitis. it provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within the chronic bronchitis pipeline insights.
Smoking Cessation Drug Pipeline Analysis Report 2025
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share